Ironwood Pharmaceuticals is a biotechnology company utilizing its development and commercial capabilities as it brings various medicines to patients. The company's commercial product, linaclotide, is available to adult men and women suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation in certain countries. The company is developing another gastrointestinal development program, IW-3718, a gastric retentive formulation of a bile acid sequestrant for the potential treatment of uncontrolled gastroesophageal reflux disease. The company is commercializing in the U.S. two products within its uncontrolled gout program, DUZALLO? (lesinurad and allopurinol) and ZURAMPIC? (lesinurad).